Successful Oxaliplatin Desensitization After Omalizumab Administration

Author:

KATRAN ZEYNEP YEGİN1ORCID,Bulut İsmet1

Affiliation:

1. Sureyyapasa Chest Diseases and Chest Surgery Training and Research Hospital: Saglik Bakanligi Istanbul Sureyyapasa Gogus Hastaliklari ve Gogus Cerrahisi EA Hastanesi

Abstract

Abstract Background: In our patient, who was diagnosed with metastatic colorectal cancer, who received a chemotherapy regimen containing oxaliplatin; We present successful desensitization after omaizumab in addition to our premedication scheme Case presentation: 39 years,F. She underwent hemicolectomy and liver metastasectomy with the diagnosis of metastatic colon adenocarcinoma. Chemotherapy regimen consisting of 5 florauracil + Bevacizumab + Oxaliplatin was started. After completing infusions of 5 florauracil while she was receiving her fourth chemotherapy; In the 20th minute of the oxaliplatin infusion, redness and itching began in the palms. While her whole body was red,she had abdominal pain, low back pain, she had no other systemic findings. His blood pressure was 90/60 mmHg. With premedication, oxaliplatin was given in 12 dilutions of 3 bottles with the M.Castel scheme. In the 11th step, at the 5th minute, redness and itching developed on the face and palms. She stated that she had chest and abdominal pain with hypotansıon. After the current condition was treated, 92 mg of oxaliplatin could be given while the target dose was 120 mg . , a single dose of omalizumab 150 mg sc was administered the day before. Standard premedication was also given. The infusion was prepared as 4 bottles of 16 steps. The first three bottles were completed without any problems. Based on her previous reaction, additional premedication was given after Step 14.The desensitization scheme was successfully completed by taking the target dose of 120 mg in total. Conclusıons: We were able to reach the target oxaliplatin dose successfully after our omalizumab administration an additional day before. Although more studies are needed on this subject, we think that omalizumab can be added to the standard premedication schemes of clinics in high-risk patients.

Publisher

Research Square Platform LLC

Reference9 articles.

1. Leucovorin and fluorouracil with or without oxaliplatin as. first-line treatment in advanced colorectal cancer;Gramont A;J Clin Oncol,2000

2. Oxaliplatin –associated hypersensititivity reactions: Clinical presebtation and management;Hewitt MR;Clin Colorectal Cancer,2006

3. Diagnostic and predictive value of skin testing in platinum salt hypersensitivity;Lugey-Seguin V;J Allergy Clin Immunol,2007

4. Lim KH. Huang MJ.Lin HC. Et. al. Hypersensitivity reactions to oxaliplatin: A case report and the success of a continuous infusional desensitization Schedule. Anticancer Drugs. 2004¸15: 605–607.

5. Hypersensitivity reactions to oxaliplatin and application of a desensitization protocol;Gammon D;Oncologist,2004

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3